Swedish Orphan Biovitrum AB (publ) is committed to upholding a strong set of values and corporate philosophy. The company prioritizes patient well-being and aims to make a positive impact on the lives of individuals affected by rare diseases. Swedish Orphan Biovitrum AB (publ) embraces an open and collaborative approach, fostering innovation and learning within the healthcare industry. With a focus on delivering high-quality therapies, the company strives to be a trusted partner for patients, healthcare providers, and society as a whole. Swedish Orphan Biovitrum AB (publ) consistently demonstrates its dedication to integrity, excellence, and sustainable practices.

Swedish Orphan Biovitrum AB (publ) primarily operates in various countries and regions worldwide. The company has a global presence, with a significant focus on Europe. It has established a strong presence in Nordic countries such as Sweden, Norway, Denmark, and Finland. Additionally, Swedish Orphan Biovitrum AB (publ) has expanded its operations to other European countries, including the United Kingdom, Germany, France, Italy, Spain, and Switzerland. It also has a growing presence in North America, particularly in the United States and Canada. Moreover, the company is actively exploring opportunities in emerging markets to further expand its geographical footprint.

Swedish Orphan Biovitrum AB has accomplished several significant milestones. Notably, the company successfully launched Elocta, a treatment for hemophilia, in multiple countries. It gained regulatory approvals for Alprolix, a therapy for hemophilia B, and Orfadin, a medication for the treatment of hereditary tyrosinemia type 1. Swedish Orphan Biovitrum AB (publ) also established strategic partnerships, including collaborations with Bioverativ, Biogen, and Novimmune. Moreover, the company expanded its product pipeline through acquisitions, such as Dova Pharmaceuticals and Emalex Biosciences. These achievements solidify Swedish Orphan Biovitrum AB's position as a leader in providing innovative treatments for rare diseases.

Swedish Orphan Biovitrum AB (publ) is a multinational pharmaceutical company focused on rare diseases and specialty care. Established in 2001, it has a rich history of developing innovative therapies to address unmet medical needs. The company operates across several therapeutic areas, including hematology, immunology, and genetic diseases. Swedish Orphan Biovitrum AB (publ) collaborates with partners worldwide to advance their extensive product portfolio, leveraging their expertise to improve patients' lives. With a strong commitment to research and development, the company continues to make significant contributions to the field of healthcare. Swedish Orphan Biovitrum AB (publ) is dedicated to driving advancements in rare diseases and expanding access to life-changing treatments.

The main competitors of Swedish Orphan Biovitrum AB (publ) in the market include companies such as Novartis AG, Roche Holding AG, Biogen Inc., and Takeda Pharmaceutical Company Limited. These pharmaceutical companies operate in a similar market segment and represent strong competition for Swedish Orphan Biovitrum AB (publ).

Swedish Orphan Biovitrum AB (publ) is primarily active in the pharmaceutical industry.

The business model of Swedish Orphan Biovitrum AB (publ) focuses on developing and commercializing innovative treatments for rare diseases. The company specializes in providing therapies that address unmet medical needs, primarily within the areas of hematology, immunology, and genetic diseases. Swedish Orphan Biovitrum AB (publ) engages in extensive research and development efforts to create effective and safe drugs for patients, collaborating with various partners in the healthcare industry. By prioritizing rare diseases and leveraging its expertise, Swedish Orphan Biovitrum AB (publ) aims to improve the lives of patients worldwide through its specialized treatments.

สัดส่วนราคาต่อกำไรของ Swedish Orphan Biovitrum AB (publ) คือ 18.09

KUV ของ Swedish Orphan Biovitrum AB (publ) คือ 3.58

AlleAktien คุณภาพสกอร์สำหรับ Swedish Orphan Biovitrum AB (publ) คือ 3/10.

คาดหวัง Swedish Orphan Biovitrum AB (publ) มียอดขายอยู่ที่ 28.81 ล้านล้าน SEK

กำไร คาดหวัง Swedish Orphan Biovitrum AB (publ) คือ 5.7 ล้านล้าน SEK

Swedish Orphan Biovitrum AB is a biopharmaceutical company specializing in rare diseases and specialty medicines. It is divided into three main business areas: coagulation disorders, immunology, and genetics. The company develops, manufactures, markets, and distributes medications for these rare diseases. The coagulation disorders division focuses on products for the treatment of hemophilia, thrombosis prevention, and bleeding. The immunology division focuses on products for the treatment of rare diseases such as hereditary angioedema and primary immune thrombocytopenia. The genetics division focuses on products for the treatment of rare genetic diseases such as Gaucher's disease, Fabry disease, and Pompe disease. The company distributes its products globally and works closely with patient organizations and healthcare providers to ensure access to medication and information for patients with rare diseases. The company also invests heavily in research and development for new therapies and diagnostic procedures for rare diseases. The business model of Swedish Orphan Biovitrum is based on the production and marketing of specialty medicines for the treatment of rare diseases. It focuses on niche markets where it has strong expertise and collaborates with patient organizations and healthcare providers to meet patient needs. The company achieves high value creation and builds a differentiated competitive advantage by focusing on rare diseases.

Swedish Orphan Biovitrum AB (publ) จ่ายเงินปันผล 0 SEK ผ่าน ครั้งในหนภายในหนึ่งปี.

ปัจจุบันไม่สามารถคำนวณเงินปันผลสำหรับ Swedish Orphan Biovitrum AB (publ) หรือบริษัทไม่จ่ายเงินปันผล.

ISIN ของ Swedish Orphan Biovitrum AB (publ) คือ SE0000872095

WKN ของ Swedish Orphan Biovitrum AB (publ) คือ A0LA5K.

ตัวย่อของ Swedish Orphan Biovitrum AB (publ) คือ SOBI.ST

ภายในช่วง 12 เดือนที่ผ่านมา Swedish Orphan Biovitrum AB (publ) จ่ายเงินปันผลทั้งหมด นี้เทียบเท่ากับอัตราผลตอบแทนจากเงินปันผลประมาณ สำหรับ 12 เดือนข้างหน้า Swedish Orphan Biovitrum AB (publ) คาดว่าจะจ่ายเงินปันผลทั้งหมด 0 SEK

อัตราผลตอบแทนเงินปันผลของ Swedish Orphan Biovitrum AB (publ) ในปัจจุบันคือ

Swedish Orphan Biovitrum AB (publ) จ่ายเงินปันผลทุกไตรมาส การจ่ายเงินปันผลจะเกิดขึ้นในเดือน

Swedish Orphan Biovitrum AB (publ) จ่ายเงินปันผลทุกปีในช่วง 0 ปีที่ผ่านมา.

คาดว่าในช่วง 12 เดือนข้างหน้าจะมีการจ่ายเงินปันผลทั้งหมด 0 SEK ซึ่งเทียบเท่ากับผลตอบแทนจากเงินปันผลร้อยละ 0 %

Swedish Orphan Biovitrum AB (publ) ถูกจัดให้อยู่ในภาคส่วน 'สุขภาพ'

เพื่อรับเงินปันผลล่าสุดของ Swedish Orphan Biovitrum AB (publ) ในวันที่ 8/1/2568 ที่มูลค่า 0 SEK คุณจะต้องถือหุ้นไว้ในพอร์ตก่อนวันที่เป็น Ex-Tag ในวันที่ 8/1/2568

การจ่ายเงินปันผลครั้งล่าสุดเกิดขึ้นเมื่อวันที่ 8/1/2568

ในปี 2024 บริษัท Swedish Orphan Biovitrum AB (publ) ได้จ่ายเงินปันผลเป็นจำนวน 0 SEK

เงินปันผลของ Swedish Orphan Biovitrum AB (publ) จะถูกจ่ายใน SEK